Evidence mapPaperPMID 40528540Full record

ReviewSmall (Weinheim an der Bergstrasse, Germany)2026

From Membrane Composition to Antimicrobial Strategies: Experimental and Computational Approaches to AMP Design and Selectivity.

Paolo Rossetti, Marius F W Trollmann, Christina Wichmann, Thomas Gutsmann, Christian Eggeling, Rainer A Böckmann

Abstract readReview
In one paragraph

Review in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Threat and Control ofFoods (Basel, Switzerland) · 2025
    Review
  4. Peptide-Based Strategies AgainstPharmaceuticals (Basel, Switzerland) · 2025
    Review
  5. Review
  6. Interactions ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paolo RossettiComputational Biology, Department of Biology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, 91058, Erlangen, Germany.
Marius F W TrollmannComputational Biology, Department of Biology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, 91058, Erlangen, Germany.ORCID https://orcid.org/0000-0002-5696-7451
Christina WichmannInstitute of Applied Optics and Biophysics, Friedrich-Schiller University Jena, 07743, Jena, Germany.
Thomas GutsmannDivision of Biophysics, Research Center Borstel, Leibniz Lung Center, 23845, Borstel, Germany.ORCID https://orcid.org/0000-0001-5061-7891
Christian EggelingInstitute of Applied Optics and Biophysics, Friedrich-Schiller University Jena, 07743, Jena, Germany.ORCID https://orcid.org/0000-0002-3698-5599
Rainer A BöckmannComputational Biology, Department of Biology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, 91058, Erlangen, Germany.

Funding

Deutsche Forschungsgemeinschaft BO2963/10-1Leibniz-Gemeinschaft AMPEL
6 · The paper itself

Abstract

The United Nations have committed to end the epidemics of communicable diseases by 2030 (SDG Target 3.3). In contrast with this ambition, the rise of Multi Drug Resistant (MDR) and Pan Drug Resistant (PDR) bacteria poses a threat of a return to the pre-antibiotic era. It is of high priority to find new therapies that target the ESKAPEE group of pathogens and their drug-resistant strains. Antimicrobial peptides (AMPs) are an emerging class of antibiotics that hold promises of overcoming bacterial resistance by using both novel mechanisms of action as well as targeting already known pathways. The chemical space of AMPs is potentially huge and methodologies allowing the rational exploration of novel structures are highly needed. This review focuses on case studies that give novel insights about the mechanisms of action, resistance and selectivity of some relevant AMPs, exemplifying the importance of microscopic, computational and experimental tools. Particular focus will be devoted to bacterial membranes and how AMPs can target them while sparing human plasma membranes, in order to become safer drugs. The lessons learned from the literature cases give directions toward the development of AMPs as drug products.

Indexed as

Anti-Infective AgentsAntimicrobial PeptidesCell MembraneDrug DesignAnti-Bacterial AgentsHumansAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial Peptidesantimicrobial peptidesantimicrobial resistancebacterial membranemachine learningmolecular dynamics simulationpeptide designplasma membrane

Identifiers

PMID40528540
PMCPMC12994565

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.